Methods of identifying risk of vascular endothelial growth factor (VEGF) pathway inhibitor-induced hypertension

摘要

The disclosure relates to methods of identifying subjects at risk of developing bevacizumab-induced toxicities such as proteinuria and/or hypertension involving measuring nucleic acid or gene mutations in a sample obtained from the subject.